Chuang Wu, PhD
Neurology · Providence, RINPI 1184661837
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,650 of the $14,204 with a category attached, or 89.1%. Lilly USA, LLC accounts for 77.1% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $9,698 and has fallen 88.7% since, to $1,100 in 2024.
Across 9 payments — averaging $1578.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$11K
- Eisai Inc.$2K
- Lundbeck LLC$1K
- Biogen$131
Across 71 payments — averaging $17,218 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$704K
- Eli Lilly$257K
- AbbVie$178K
- Avanir Pharmaceuticals, Inc.$31K
- Janssen Research & Development, LLC$27K
- E.r. Squibb & Sons, L.L.C.$26K
- plus $158 from 1 others
What the payments were for
- Consulting fees$12,65089%
- Speaking & faculty fees$1,1008%
- Travel & lodging$3232%
- Food & beverage$1311%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 5 | $10,948 |
| Eisai Inc. | 1 | $2,025 |
| Lundbeck LLC | 1 | $1,100 |
| Biogen | 2 | $131 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$1,100
How this compares
$14,204 in reported general payments places this provider in the 80th percentile of 86 neurology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 18 | $29,009 |
| Memantine Hcl | 362 | $16,428 |
| Memantine Hcl ErMemantine Hcl | 164 | $12,537 |
| Donepezil Hcl | 631 | $7,717 |
| Galantamine ErGalantamine Hbr | 95 | $7,599 |
| Rivastigmine | 22 | $5,309 |
| Galantamine Hbr | 22 | $1,582 |
| Levetiracetam | 19 | $771 |
| Trazodone Hcl | 83 | $594 |
| Quetiapine Fumarate | 44 | $500 |
| Citalopram HbrCitalopram Hydrobromide | 54 | $477 |
| Sertraline Hcl | 36 | $294 |
| Escitalopram Oxalate | 18 | $248 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 12 | $186 |
| Gabapentin | 19 | $149 |
Paid to pharmacies, not to this prescriber.
Other neurology in Providence
- Stephen SallowayProvidence$329K
- Syed RizviProvidence$160K
- John EastonProvidence$112K
- Saima ChaudhryProvidence$90K
- Monica DhakarProvidence$45K
- Jeffrey WishikProvidence$34K
- Prathana PrakashProvidence$31K
- Karen FurieProvidence$29K
- Emily WeisbachProvidence$11K
- Shawn TsekhanProvidence$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.